Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06001788 · ClinicalTrials.gov registry record · Phase 1

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 study of Acute Myeloid Leukemia and Leukemia, sponsored by Kura Oncology.

Recruiting
Registry status
Phase 1
Development phase
171
Enrollment target
20
Study locations

NCT06001788 is a Phase 1 study of Acute Myeloid Leukemia and Leukemia that is actively recruiting participants, run by Kura Oncology. The registered enrollment target is 171 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06001788, a Phase 1 study of Acute Myeloid Leukemia and Leukemia, is actively recruiting participants, sponsored by Kura Oncology.

RECRUITING
Registry status
Phase 1
Development phase
171 participants
Enrollment target
20
Study locations

Study Summary

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Conditions Studied

Acute Myeloid Leukemia Leukemia Hematologic Malignancy Leukemia, Myeloid, Acute AML Leukemia, Myeloid NPM1 Mutation AML With Mutated NPM1 KMT2Ar MLL Rearrangement

Interventions

  • DRUG Fludarabine
  • DRUG Cytarabine
  • DRUG Idarubicin
  • DRUG Gilteritinib
  • DRUG Ziftomenib

Study Locations (20)

California

  • USC Norris Comprehensive Cancer Center - Los Angeles
  • UCLA Health - Bowyer Oncology Center - Los Angeles
  • UC Irvine Health Chao Family Comprehensive Cancer Center - Orange
  • University of California San Francisco - San Francisco

Illinois

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
  • Loyola University Medical Center - Maywood
  • Simmons Cancer Institute - Springfield

Georgia

  • Emory Healthcare - The Emory Clinic - Atlanta
  • Georgia Cancer Center at Augusta University - Augusta

Michigan

  • Karmanos Cancer Institute - Detroit
  • Henry Ford Cancer Institute - Detroit

Arizona

  • Banner MD Anderson Cancer Center - Gilbert

Colorado

  • Colorado Blood Cancer Institute - Denver

Connecticut

  • Smilow Cancer Hospital at Yale New Haven - New Haven

Iowa

  • University of Iowa Hospitals & Clinics - Iowa City

Trial Details

FieldValue
Enrollment Target 171 participants
Start Date 2024-02-22
Est. Completion 2027-08
Phase Phase 1

Sponsor

Kura Oncology

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06001788

The ClinicalTrials.gov registry entry for NCT06001788 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (49% higher). The listed sponsor is Kura Oncology, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.

NCT06001788 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Illinois, Georgia.

Frequently Asked Questions

What is clinical trial NCT06001788 about?

NCT06001788 is a clinical study titled "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia". The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

What is the current status of trial NCT06001788?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 171 participants. The study started on 2024-02-22. Estimated completion is 2027-08.

What conditions does trial NCT06001788 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Leukemia, Hematologic Malignancy, Leukemia, Myeloid, Acute, AML.

What interventions are being tested in trial NCT06001788?

The interventions under investigation include: Fludarabine (DRUG), Cytarabine (DRUG), Idarubicin (DRUG), Gilteritinib (DRUG), Ziftomenib (DRUG).

Who is sponsoring clinical trial NCT06001788?

This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06001788 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Leukemia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.